RxDoctor Payments Data

Lenay Santana, MD

Neurology · Fort Myers, FLNPI 1124215538

Payments from drug & device makers

$2,158in general payments, 2019–2025

Across 65 payments — averaging $33.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$544
  • Argenx US, Inc.$365
  • Amgen$201
  • UCB, Inc.$147
  • Neurelis, Inc.$121
  • Eisai Inc.$121
  • plus $658 from 17 others

What the payments were for

  • Food & beverage$2,158100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,158 in reported general payments places this provider in the 45th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$10,404
Medicare patients
75
Services billed
109

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Emgality PenGalcanezumab-Gnlm125$129,503
UbrelvyUbrogepant120$127,006
Kesimpta PenOfatumumab12$105,360
Nurtec OdtRimegepant Sulfate69$104,729
Trokendi XrTopiramate51$98,786
Aimovig AutoinjectorErenumab-Aooe88$88,124
Gamunex-CImmune Globul G/Gly/Iga Avg 4611$81,102
NeuproRotigotine25$33,660
Ajovy AutoinjectorFremanezumab-Vfrm31$31,174
BriviactBrivaracetam12$17,340
Carbidopa-LevodopaCarbidopa/Levodopa235$6,475
Entacapone27$5,886
Pyridostigmine Bromide59$5,790
Sumatriptan Succinate140$5,550
Memantine Hcl138$5,019

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy$30$127,006120 claims
Supernus Pharmaceuticals, Inc.Trokendi Xr$26$98,78651 claims
UCB, Inc.Neupro, Briviact$147$51,00037 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,434 neurology providers in Florida.

Other neurology in Fort Myers

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →